CTOs on the Move

Royal Danish Consulate

www.investindk.com

 
Royal Danish Consulate is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.investindk.com
  • 1 California St Ste 330
    San Francisco, CA USA 94111
  • Phone: 212.223.4545

Executives

Name Title Contact Details

Similar Companies

Korro Bio

Korro Bio is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and common diseases. The company`s proprietary and modular platform, OPERA™ (Oligonucleotide promoted editing of RNA), builds on a deep understanding of ADAR biology, and combines data-driven design, oligo discovery and chemistry with clinically validated delivery vehicles, to achieve highly selective RNA editing. This unique technology enables the development of RNA editing therapeutics that deliver the functional benefits of gene therapy with a reversible, transient, titratable and specific treatment regimen, offering the potential to propel genetic medicine beyond rare genetic diseases into larger patient populations with common diseases. Korro is based in Cambridge, Mass.

AbCellera

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. Its full-stack, AI-powered drug discovery platform integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. We partner with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development.

Be Biopharma

Be Biopharma is a leader in developing B cells as medicines, treating disease with the human body`s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, allogeneic, re-dosable, and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., Be Biopharma is re-imagining medicine based on the power of B cell therapy. Be Bio was founded in October 2020 by Longwood Fund with a $52 million Series A investment led by Atlas Ventures and RA Capital, joined by Alta Partners and Takeda Ventures.

Novus Therapeutics

Novus Therapeutics, Inc. (NASDAQ: NVUS) is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease.

Receptor Life Sciences

Receptor Life Sciences, Inc. develops inhaled therapeutic products for conditions including chronic pain, neurologic diseases, and inflammatory disorders.